DETECTING EGFR MUTATIONS IN PATIENTS
WITH NON-SMALL CELL LUNG CANCER
Hammoudeh ZA, Antonova O, Staneva R, Nikolova D, Kyuchukov Y,
Penev A, Mintchev T, Koleva V, Hadjidekova S, Toncheva D
*Corresponding Author: Zora A. Hammoudeh, Molecular Biologist, Department of Medical Genetics, Medical University Sofia,
2 Zdrave Str., 1431 Sofia, Bulgaria. Tel: +359-2-917-2735. Mobile: +359-88-943-0505. E-mail: zorahammoudeh@yahoo.com
page: 13
|
|
REFERENCES
1. Chilingirova N, Hammoudeh Z, Balabanski L, Ivanov
S, Vazharova R, Nikolova D, et al. TruSight Cancer
Sequencing Panel reveals pharmacogenetic variants
associated with sensitivity to chemotherapy in lung
cancer. memo Magazine of European Medical Oncology.
2016; 9(1): 30-38 (https://link.springer.com/
article/10.1007/ s12254-015-0244-2.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et
al. Cancer statistics, 2008. CA Cancer J Clin. 2008;
58(2): 71-96.
3. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang
W, et al. Alterations in genes of the EGFR signaling
pathway and their relationship to EGFR tyrosine
kinase inhibitor sensitivity in lung cancer cell lines.
Plos One. 2009; 4(2): e4576.
4. Sadowska AM, Nowé V, Janssens A, Boeykens E, De
Backer WA, Germonpré PR. Customizing systemic
therapy in patients with advanced non-small cell lung
cancer. Ther Adv Med Oncol. 2011; 3(4): 207-218.
5. Rosell R, Carcereny E, Gervais R, Vergnenegre A,
Massuti B, Felip E, et al. Erlotinib versus standard
chemotherapy as first-line treatment for European
patients with advanced EGFR mutation-positive nonsmall-
cell lung cancer (EURTAC): A multicentre,
open-label, randomised phase 3 trial. Lancet Oncol.
2012; 13(3): 239-246. 6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S,
Okimoto RA, Brannigan BW, et al. Activating mutations
in the epidermal growth factor receptor underlying
responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 2004; 350(21): 2129-2139.
7. Gazdar AF. Activating and resistance mutations of
EGFR in non-small-cell lung cancer: role in clinical
response to EGFR tyrosine kinase inhibitors. Oncogene.
2009; 28(Suppl 1): S24-S31.
8. Pao W, Miller V, Zakowski M, Doherty J, Politi K,
Sarkaria I, et al., EGF receptor gene mutations are
common in lung cancers from “never smokers” and
are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 2004;
101(36): 13306-13311.
9. Jänne PA, Gurubhagavatula S, Yeap BY, Lucca J,
Ostler P, Skarin AT, et al. Outcomes of patients with
advanced non-small cell lung cancer treated with
gefitinib (ZD1839, ‘Iressa’) on an expanded access
study. Lung Cancer. 2004; 44(2): 221-230.
10. Khuder SA. Effect of cigarette smoking on major
histological types of lung cancer: A meta-analysis.
Lung Cancer. 2001; 31(2-3): 139-148.
11. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal
growth factor receptor mutations in lung cancer.
Nat Rev Cancer. 2007; 7(3): 169-181.
12. Maemondo M, Inoue A, Kobayashi K, Sugawara S,
Oizumi S, Isobe H, et al. Gefitinib or chemotherapy
for non-small-cell lung cancer with mutated EGFR.
N Engl J Med. 2010; 362(25): 2380-2388.
13. Jänne PA, Wang X, Socinski MA, Crawford J, Stinchcombe
TE, Gu L, et al., Randomized phase II trial
of erlotinib alone or with carboplatin and paclitaxel
in patients who were never or light former smokers
with advanced lung adenocarcinoma: CALGB 30406
Trial. J Clin Oncol. 2012; 30(17): 2063-2069.
14. Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer
is ready for prime time. Lancet Oncol. 2009; 10(5):
432-433.
15. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H,
Gabriel S, et al. EGFR mutations in lung cancer:
Correlation with clinical response to gefitinib therapy.
Science. 2004; 304(5676): 1497-1500.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
